HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenstrom's macroglobulinemia.

Trial Profile

HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenstrom's macroglobulinemia.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOVON 124 WM
  • Most Recent Events

    • 17 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top